Pittsburgh Launches Rare Ventures with $25M to Accelerate Rare-Disease Therapies
The Richard King Mellon Foundation is launching Rare Ventures in Pittsburgh with $25 million to create a three-year, venture‑philanthropy hub that unites universities, biotech firms, and EB Research Partnership to accelerate rare-disease drug development. The initiative will use an AI tool called Curator to centralize deidentified patient genetic data for trial matching, with a goal of becoming self‑sustaining by funneling revenues from approved therapies back into future research and expanding collaborations across Pitt, CMU, ElevateBio, UPMC, and Stanford.